256 - Can Cell Therapy Reverse Hearing Loss? Latest Update on Development of the ReSonance™ Program

Can cell therapy revolutionize hearing loss treatment? In this follow-up discussion, Brian Culley, CEO of Lineage Cell Therapeutics, shares exciting updates on the ReSonance™ (ANP1) program, a pioneering preclinical study exploring auditory neuron cell transplantation. Culley explains how lab-grown auditory neurons are being delivered to the inner ear to potentially restore damaged auditory pathways—a groundbreaking approach that could even complement existing treatments. In this conversation, Culley sheds light on the preclinical results, including the successful delivery of auditory neurons in animal models, and discusses the challenges and opportunities ahead as Lineage prepares for clinical trials. The discussion also touches on the broader implications of cell therapy and its potential integration into hearing care solutions. Interested in the latest in cell therapy and other cutting-edge hearing loss treatments under development? You won't want to miss out on the Hearing Therapeutics Virtual Summit. Taking place from February 4-5. Learn more and register here: https://www.accelevents.com/e/Hearing-Therapeutics-Summit For more information on the ReSonance program, visit the company's website here. Be sure to subscribe to our YouTube channel for the latest episodes each week, and follow This Week in Hearing on LinkedIn and X (formerly Twitter): https://www.linkedin.com/company/this-week-in-hearing/ https://twitter.com/WeekinHearing